Axios AI+ NY Summit: AI's rapid rise outpaces guardrails
NEW YORK – AI and the internet are outpacing oversight — threatening kids, creatives, national security and even basic innovation, leaders across tech, politics and entertainment said at the Axios' AI+ Summit.
Why it matters: AI is transforming industries and society faster than it can be regulated, creating sweeping, serious security risks, according to several speakers.
The June 4 summit hosted multiple conversations and was sponsored by BCG, Booking Holdings, Snyk, Varonis, and Workato.
Here are some key takeawayes:
WndrCo founding partner Jeffrey Katzenberg said kids' unsupervised use of the internet is "destroying a generation."
Lumen Technologies president and CEO Kate Johnson said telcos aren't innovative enough and have ceded too much ground to Big Tech.
The Weather Company CEO Rohit Agarwal said AI could help forecasters be as specific as giving guidance on what time of day to walk your dog.
Gov. Kathy Hochul (D-N.Y.) made a dig at Rep. Marjorie Taylor Greene (R-Ga.) for saying she didn't know the GOP's "big, beautiful" tax bill included a provision that would ban states and municipalities from regulating the tech for 10 years.
Lux Capital co-founder Josh Wolfe said the best way to beat China in the AI race is to "make sure every single young" person is super well-versed in AI.
Actor and entrepreneur Joseph Gordon-Levitt said there needs to be an incentive to keep creatives paid and employed as AI disrupts the entertainment business.
Content from the sponsored View from the Top conversations:
Vlad Lukić, BCG managing director and senior partner, and global leader for its tech & digital advantage practice discussed the disconnect between corporate AI investment and tangible outcomes.
According to a recent study of 1,000 companies, "Over 75% of them are with budgets in this year deploying AI at scale, but only 25% of them have a line of sight to value creation from those activities," he added.
Danny Allan, chief technology officer at Snyk, said visibility, false expectations, and proper policies are lacking behind the pace of AI-powered software development.
"The speed and velocity that software is coming through the pipelines is like nothing I have ever seen in my career right now. It's so, so fast. And the trouble that CISOs have is they don't have the trust that what is coming through that pipeline is actually secure."
Bhaskar Roy, Workato chief of AI products and solutions, said businesses will experience real transformation when AI agents tackle the "messy middle."
"There are a few companies that are targeting the core and looking at how they can transform the core with … agentic AI and that's what excites us."
Rob Sobers, chief marketing officer at Varonis, warned that security risks, like "AI model poisoning" where attackers inject malicious data into AI models, could impact people's lives.
While working with an organization researching Alzheimer's, they noticed a hacker feeding the organization's custom AI model new data out of nowhere, Sobers said. And, "that could change subtly the dosage of a medication that you're giving somebody. … It's super important to get the trust and security layer right."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Trump's AI czar downplays risk AI chip exports could be smuggled
White House AI czar David Sacks on Tuesday downplayed the risk that coveted American AI chips could be smuggled to bad actors, and expressed concern that regulating U.S. AI too tightly could stifle growth and cede the critical market to China. "We talk about these chips like they could be smuggled in the back of a briefcase. That's not what they look like. These are server racks that are eight feet tall and weigh two tons," Sacks said at the AWS summit in Washington."They don't walk out doors. It's very easy to basically verify that they're where they're supposed to be," he said. The comments indicated President Donald Trump's approach to AI could be centered on expanding markets abroad for U.S. AI chips and models. Former President Joe Biden had emphasized policies that countered risks the chips could be diverted to China and used to bolster Beijing's military."I do worry we're on a trajectory where fear could overtake opportunity and we end up sort of crippling this wonderful progress that we're seeing," Sacks said, citing a raft of bills in state legislatures seeking to regulate AI, as well as permitting challenges facing companies seeking to build the data centers that power AI. Trump rescinded Biden's executive order aimed at promoting competition, protecting consumers and ensuring AI was not used for misinformation. He also rescinded Biden's so-called AI diffusion rule, which capped the amount of American AI computing capacity that some countries were allowed to obtain via U.S. AI chip imports."We rescinded that Biden diffusion rule, diffusion a bad word. Diffusion of our technology should be a good word," Sacks said. The Trump administration and the United Arab Emirates also announced a plan last month for the Gulf country to build the largest artificial intelligence campus outside the U.S. after Biden in 2023 put in place rules that curbed most AI chip shipments to the aim at that regulation, Sacks said, "What play are we giving them? We're basically going to push them into the arms of China."He added that if, in five years, AI chips made by sanctioned Chinese telecoms equipment giant Huawei were everywhere, "that means we can't let that happen."The need to remove hurdles to U.S. AI innovation is urgent as China has made important advances in its AI models, Sacks said. This year, the Chinese AI app DeepSeek shocked the world with its sophisticated, affordably trained model. "China is not years and years behind us in AI. Maybe they're three to six months," said Sacks. "It's a very close race." The White House later said he was referring to China's AI models, adding that Chinese AI chips are one to two years behind their U.S. counterparts.
Yahoo
an hour ago
- Yahoo
AI storage platform Vast Data aimed for $25B valuation in new round, sources say
Vast Data, which offers an AI-friendly data storage platform, is in the market to raise a new round at a giant leap in valuation. Earlier this year, the 9-year-old company was seeking a valuation of around $25 billion, according to a person familiar with the deal. Should it achieve that, it would be a massive jump from its $9 billion Series E valuation secured in December 2023. The deal was not finalized, and terms -- including its valuation -- could change, this person said, adding that the requested valuation was high at the time, despite impressive growth. Many VCs are interested in and watching Vast, other sources tell TechCrunch. Vast didn't respond to a request for comment. Vast Data offers data management software coupled with unified CPU, GPU, and data hardware from vendors like Supermicro, HPE, and Cisco. Whereas old-school data storage options rely on tiers (low-cost storage options for long-term storage, higher-end options for more frequently used data), Vast aims to eliminate such tiers. It is particularly aimed at flash storage. AI has been a boon to Vast's business. The company's platform stores structured, semi-structured, and unstructured data in one place, which accelerates data retrieval and, it says, reduces the cost of model training and inference. The company's customers include large enterprises such as Pixar, ServiceNow, and xAI, as well as next-generation AI cloud providers like CoreWeave and Lambda, which use Vast's technology to offer storage capabilities to their end users. Vast had annual recurring revenue (ARR) of $200 million when it raised its Series E about 18 months ago, TechCrunch reported. The company has been growing at 2.5x to 3x year-over-year, Renen Hallak, Vast's CEO and co-founder, said on a podcast last May. The company has also been free cash flow positive for four years, Hallak said. On data storage capabilities, Vast competes with 16-year-old publicly traded Pure Storage that has a market capitalization of nearly $17 billion, and 12-year-old Weka, which last year raised a $140 million round at a $1.6 billion valuation. Vast is also developing a database architecture that is competitive with Databricks' offering. Prior to the round it is currently working on, the company has raised a total of $381 million from investors, including Fidelity Management & Research Company, NEA, BOND Capital, and Drive Capital. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Sen. Collins grills NIH director on research cuts
Jun. 10—Dr. Jay Bhattacharya, the new director of the National Institutes of Health, faced sharp questions from Sen. Susan Collins and other senators Tuesday about a proposed 40% budget reduction at the NIH and other cutbacks that are disrupting biomedical research. Bhattacharya appeared before the Senate Appropriations Committee's subcommittee on labor, health and human services and education on Tuesday as the Trump administration has slashed funding for biomedical research and public health. On Monday, hundreds of NIH scientists signed a letter, called the "Bethesda Declaration," asking the Trump administration to protect funding for biomedical research. Also Monday, Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns among public health advocates when he summarily dismissed all 17 members of a key committee that advises the government on approving vaccines. Kennedy, who has falsely questioned the safety and efficacy of vaccines, has not said who he would place on the Advisory Committee on Immunization Practices, which among other duties, recommends the formulation for the annual influenza vaccine. At the Senate hearing Tuesday, Bhattacharya largely dodged questions about the Trump administration's proposals to slash the agency, and the ongoing cuts to research grants. Collins, who voted to confirm Bhattacharya but has decried NIH cuts, questioned why the Trump administration is requesting a $19 billion cut to the NIH in the 2026 budget, which she said would "undo years of congressional investment." "It would delay or stop effective treatments and cures being developed for diseases like Alzheimer's, cancer and Type 1 diabetes," said Collins, who is chair of the Appropriations Committee. "We also risk falling behind China and other countries that are increasing their investment in biomedical research." Bhattacharya said the agency is "fully committed" to making progress on Alzheimer's and that the 2026 budget will be a "collaboration" between Congress and the White House. But, despite getting a series of questions from Collins and other Republican and Democratic senators, Bhattacharya did not specifically address the rationale for the budget cuts. Collins has also been speaking out for months against the agency's moves to cap the amount of money that biomedical researchers can use for indirect costs at no more than 15% of their NIH grants. The indirect costs include overhead expenses, equipment and technical support for scientific research and scientists say the cap would hobble research laboratories in Maine and across the country. The amount that NIH grants pay for indirect costs varies by grant, but made up 26% of the cost of each grant, on average, in 2023. Collins has also directly lobbied Kennedy to reverse the NIH cap on indirect costs, and Maine has joined other states in a lawsuit to block the cuts. On Tuesday, Collins said she is still "alarmed and surprised the administration's budget request (for next year) contains the same 15% cap." Bhattacharya said he couldn't discuss the indirect costs issue because of the pending lawsuit, but that there's "lots of great possibilities for reform" on how NIH awards grants for research. Sen. Tammy Baldwin, D-Wisconsin, also pointed out that the NIH has so far in 2025 spent $3 billion less on biomedical research compared to the same time in 2024, largely by freezing or denying grant funding on research that Congress previously approved. Much of the denied funding is the subject of pending lawsuits by states and universities that argue the Trump administration is illegally blocking the funding. The lawsuits argue that the executive branch is required to spend money that Congress approves, and the Trump administration does not have the power to block previously approved funding. "How is this anything other than sabotaging biomedical research?" Baldwin said. Bhattacharya did not answer, except to say he's "happy to work with Congress" on funding issues. Sen. Richard Durbin, D-Illinois, said the cuts to research are disturbing. "For God's sake, we lead the world in medical research. Why would we walk away from it?" Durbin said. Copy the Story Link
